Mavacamten: First Approval

被引：55
作者：
Keam, Susan J. [1 ]
机构：
[1] Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2022年 / 82卷 / 10期
关键词：
OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY; EXPLORER-HCM; DOUBLE-BLIND; TASK-FORCE; DIAGNOSIS; CONTRACTILITY; SENSITIVITY; MANAGEMENT; ADULTS;
D O I：
10.1007/s40265-022-01739-7
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Mavacamten (Camzyos (TM)) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. In April 2022, mavacamten was approved for use in the USA in the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms. This article summarizes the milestones in the development of mavacamten leading to this first approval for the treatment of adults with symptomatic NYHA class II-III obstructive HCM.
引用
收藏
页码：1127 / 1135
页数：9
相关论文
共 49 条
  • [1] American College of Cardiology, 2022, EFF SAF MAV TREAT OB
  • [2] Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers
    Anderson, Robert L.
    Trivedi, Darshan V.
    Sarkar, Saswata S.
    Henze, Marcus
    Ma, Weikang
    Gong, Henry
    Rogers, Christopher S.
    Gorham, Joshua M.
    Wong, Fiona L.
    Morck, Makenna M.
    Seidman, Jonathan G.
    Ruppel, Kathleen M.
    Irving, Thomas C.
    Cooke, Roger
    Green, Eric M.
    Spudich, James A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (35) : EB143 - EB152
  • [3] [Anonymous], 2022, Bristol Myers Squibb provides update on CheckMate-901 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as first-line treatment for patients with unresectable or metastatic urothelial carcinoma
  • [4] [Anonymous], 2019, MYOKARDIA REG GLOB R
  • [5] Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy
    Awinda, Peter O.
    Watanabe, Marissa
    Bishaw, Yemeserach
    Huckabee, Anna M.
    Agonias, Keinan B.
    Kazmierczak, Katarzyna
    Szczesna-Cordary, Danuta
    Tanner, Bertrand C. W.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2021, 320 (02): : H881 - H890
  • [6] Effects of mavacamten on Ca2+sensitivity of contraction as sarcomere length varied in human myocardium
    Awinda, Peter O.
    Bishaw, Yemeserach
    Watanabe, Marissa
    Guglin, Maya A.
    Campbell, Kenneth S.
    Tanner, Bertrand C. W.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (24) : 5609 - 5621
  • [7] Bristol Myers Squibb, 2022, MAVACAMTEN DEMONSTRA
  • [8] Bristol Myers Squibb, 2020, MYOKARDIA BRIST MYER
  • [9] Bristol Myers Squibb, 2021, EUR MED AG VAL BRIST
  • [10] Bristol-Myers Squibb, 2020, BRIST MYERS SQUIBB A BRIST MYERS SQUIBB A
12345